Theralase Technologies (CVE:TLT) Stock Price Up 21.1% – Time to Buy?

Theralase Technologies Inc. (CVE:TLT) shares rose 21.1% during trading on Monday . The stock traded as high as C$0.23 and last traded at C$0.23. Approximately 222,201 shares were traded during mid-day trading, an increase of 98% from the average daily volume of 112,319 shares. The stock had previously closed at C$0.19.

Theralase Technologies Stock Down 12.3 %

The company has a debt-to-equity ratio of 20.58, a quick ratio of 3.40 and a current ratio of 1.21. The firm has a market cap of C$78.57 million, a PE ratio of -14.00 and a beta of 1.36. The stock has a fifty day moving average price of C$0.19 and a 200-day moving average price of C$0.18.

Theralase Technologies (CVE:TLT) last issued its earnings results on Monday, August 12th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.10 million during the quarter. Research analysts expect that Theralase Technologies Inc. will post -0.05 EPS for the current year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.